Takashi Nagai

Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma

T. Naiki, T. Etani, S. Hamamoto, 2024, Journal of clinical medicine.

Using fosfomycin to prevent infection following ureterorenoscopy in response to shortage of cephalosporins: a retrospective preliminary study

T. Naiki, T. Etani, N. Kawai, 2024, BMC urology.

Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma

T. Naiki, T. Etani, R. Ando, 2024, Scientific reports.

C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study

A. Naiki‐Ito, T. Naiki, T. Etani, 2024, Cancers.